key: cord-0953369-qt5qv3zx
authors: Jagadeesh, Karthik A.; Dey, Kushal K.; Montoro, Daniel T.; Mohan, Rahul; Gazal, Steven; Engreitz, Jesse M.; Xavier, Ramnik J.; Price, Alkes L.; Regev, Aviv
title: Identifying disease-critical cell types and cellular processes across the human body by integration of single-cell profiles and human genetics
date: 2021-11-23
journal: bioRxiv
DOI: 10.1101/2021.03.19.436212
sha: e7b830ff33471c51eb2608bab38048db6db1ad73
doc_id: 953369
cord_uid: qt5qv3zx

Genome-wide association studies (GWAS) provide a powerful means to identify loci and genes contributing to disease, but in many cases the related cell types/states through which genes confer disease risk remain unknown. Deciphering such relationships is important for identifying pathogenic processes and developing therapeutics. Here, we introduce sc-linker, a framework for integrating single-cell RNA-seq (scRNA-seq), epigenomic maps and GWAS summary statistics to infer the underlying cell types and processes by which genetic variants influence disease. We analyzed 1.6 million scRNA-seq profiles from 209 individuals spanning 11 tissue types and 6 disease conditions, and constructed gene programs capturing cell types, disease progression, and cellular processes both within and across cell types. We evaluated these gene programs for disease enrichment by transforming them to SNP annotations with tissue-specific epigenomic maps and computing enrichment scores across 60 diseases and complex traits (average N=297K). Cell type, disease progression, and cellular process programs captured distinct heritability signals even within the same cell type, as we show in multiple complex diseases that affect the brain (Alzheimer’s disease, multiple sclerosis), colon (ulcerative colitis) and lung (asthma, idiopathic pulmonary fibrosis, severe COVID-19). The inferred disease enrichments recapitulated known biology and highlighted novel cell-disease relationships, including GABAergic neurons in major depressive disorder (MDD), a disease progression M cell program in ulcerative colitis, and a disease-specific complement cascade process in multiple sclerosis. In autoimmune disease, both healthy and disease progression immune cell type programs were associated, whereas for epithelial cells, disease progression programs were most prominent, perhaps suggesting a role in disease progression over initiation. Our framework provides a powerful approach for identifying the cell types and cellular processes by which genetic variants influence disease.

Genome wide association studies (GWAS) have successfully identified thousands of diseaseassociated variants [1] [2] [3] , but the cellular mechanisms through which these variants drive complex diseases and traits remain largely unknown. This is due to several challenges, including the difficulty of relating the approximately 95% of risk variants that reside in non-coding regulatory regions to the genes they regulate [4] [5] [6] [7] , and our limited knowledge of the specific cells and functional programs in which these genes are active 8 . Previous studies have linked traits to functional elements [9] [10] [11] [12] [13] [14] [15] and to cell types from bulk RNA-seq profiles [16] [17] [18] . Considerable work remains to analyze cell types and states at finer resolutions across a breadth of tissues, incorporate disease tissue-specific gene expression patterns, model cellular processes within and across cell types, and leverage enhancer-gene links [19] [20] [21] [22] [23] to improve power.

ScRNA-seq data provide a unique opportunity to tackle these challenges 24 . Single-cell profiles allow the construction of multiple gene programs to more finely relate GWAS variants to function, including programs that reflect cell-type-specific signatures [25] [26] [27] [28] , disease progression within cell types 29, 30 , and key cellular processes that vary within and/or across cell types 31 . Initial studies have related single-cell profiles with human genetics in post hoc analyses by mapping candidate genes from disease-associated genomic regions to cell types by their expression relative to other cell types [32] [33] [34] . More recent studies have begun to leverage genome-wide polygenic signals to map traits to cell types from single cells within the context of a single tissue 35-37 . However, focusing on a single tissue could in principle result in misleading conclusions, because disease mechanisms span tissue types across the human body. For example, in the context of the colon, a neural gene associated with psychiatric disorders would appear highly specific to enteric neurons, but this cell population may no longer be strongly implicated when the analysis also includes cells from the human central nervous system (CNS) 38 . Thus, there is a need for a principled method that combines human genetics and comprehensive scRNA-seq applied across multiple tissues and organs.

Here, we develop and apply sc-linker, an integrated framework to relate human disease and complex traits to cell types and cellular processes by integrating GWAS summary statistics, epigenomics and scRNA-seq data from multiple tissue types, diseases, individuals and cells.

Unlike previous studies, we analyze gene programs that represent different facets of cells, including discrete types, processes activated specifically in a cell type in disease, and gene programs that vary across cells irrespective of cell type definitions (recovered by latent factor models). We transform gene programs to SNP annotations using tissue-specific enhancer-gene links [19] [20] [21] [22] [23] in preference to standard gene window-based linking strategies used in existing gene-set enrichment methods such as MAGMA 39 , RSS-E 13 and LDSC-SEG 18 . We then link SNP annotations to diseases by applying stratified LD score regression 11 (S-LDSC) with the baseline-LD model 40, 41 to the resulting SNP annotations. We further integrate cellular expression and GWAS to prioritize specific genes in the context of disease-critical gene programs, thus shedding light on underlying disease mechanisms.

We developed a framework to link gene programs derived from scRNA-seq with diseases and complex traits (Fig. 1a) . First, we use scRNA-seq to construct gene programs, defined as probabilistic gene sets, that characterize (1) individual cell types, (2) disease progression (disease vs. healthy cells of the same type), or (3) cellular processes (Methods). Then, we link the genes underlying these programs to SNPs that regulate them by incorporating two tissue-specific enhancer-gene linking strategies: Roadmap Enhancer-Gene Linking [19] [20] [21] and the Activity-by-Contact (ABC) model 22, 23 . Finally, we evaluate the disease informativeness of the resulting SNP annotations by applying S-LDSC 11 conditional on a broad set of coding, conserved, regulatory and LD-related annotations from the baseline-LD model 40, 41 . Altogether, our approach links diseases and traits with gene programs recapitulating cell types and cellular processes. We have released open-source software implementing the approach (sc-linker; Code Availability), a web interface for visualizing the results (Data Availability), postprocessed scRNA-seq data, gene programs, enhancer-gene linking strategies, and SNP annotations analyzed in this study (Data Availability).

We constructed three kinds of gene programs from scRNA-seq data ( Fig. 1b) : (i) cell type programs that represent genes specifically enriched in an individual broad cell type of a tissue (e.g., colon T cells) compared to other cell types in that tissue; (ii) disease progression cell type programs that represent disease progression differences in gene expression within the same cell type (e.g., colon T cells in UC vs. healthy colon); and (iii) cellular process programs that capture gene co-variation patterns within and across cell types (e.g., MHC class II antigen presenting process varying across dendritic cells and B cells) (Methods). We constructed (healthy) cell type programs by assessing the differential expression of each gene for the focal cell type vs. all other cell types in the tissue using healthy individuals (with cell types defined by clustering 42 and annotated post hoc) and transforming each gene's Z score to a probabilistic score (Methods).

(Analogous to healthy cell type programs generated from healthy tissues, we also generated disease cell type programs from cell profiles from disease tissues.) We constructed disease progression cell type programs by assessing differential expression between cells of the same type in disease vs. healthy tissue and transforming each gene's Z score to a probabilistic score (Methods), aiming to capture genes involved in disease progression and symptoms after onset.

(We caution that disease progression programs may also capture genes reflecting genetic susceptibility to disease, rather than progression.) On average, disease progression cell type programs had low correlation with healthy cell type programs of the same cell type (Pearson r=0.16 across tissues; see below) compared to the much higher correlation between disease and healthy cell type programs (average r=0.62 across tissues); thus, we did not consider disease cell type programs in any of our primary analyses. Finally, independently of predefined cell type subsets, we constructed cellular process programs using unsupervised learning, via non-negative matrix factorization 43 (NMF) and a modified NMF (to jointly model both healthy and disease states) of normalized gene expression values, with the latent factors (programs) representing variation across continuums of cell types or processes active in multiple cell types. We computed the correlations between weights of each latent factor across cells and each gene's expression across cells and then transformed them to a 0-1 probabilistic scale to define each cellular process program. We annotated each cellular process program by its most enriched pathways (Methods) and labeled it as 'intra-cell type' or 'inter-cell type' if highly correlated with only one or multiple cell type programs, respectively (Methods). Intra-cell type cellular processes can correspond to narrower cell types (e.g., CD4 T cells) reflecting cell subsets of broader cell type categories (e.g., T cells) or variation within a cell type continuum, whereas inter-cell type cellular process programs can reflect shared processes or transitions.

Next, we transformed the genes prioritized by each program into SNP annotations by linking each gene to SNPs that may regulate their activity in cis (Fig. 1a) . We generated SNP annotations using an enhancer-gene linking strategy, defined as an assignment of 0, 1 or more linked genes to each SNP, combining Roadmap Enhancer-Gene Linking (Roadmap) 19, 21 and Activity-By-Contact (ABC) 22,23 strategies (Roadmap∪ABC) in the tissue underlying the program of interest (Methods).

We used tissue level enhancer-gene links instead of cell type level enhancer-gene links because they generated more significant associations in benchmarking experiments based on current data (see below). We primarily focused on linking genes to non-coding regulatory variants (which may drive cell-type specific differences in expression), based on the results of our benchmarking experiments (see below).

Finally, we evaluated each gene program for disease heritability enrichment by applying S-LDSC 11 with the baseline-LD model 40,41 to the resulting SNP annotations (Fig. 1a, Methods) . The S-LDSC analysis was conditioned on 86 coding, conserved, regulatory and LD-related annotations from the baseline-LD model (v2.1) 40,41 (Data Availability), and uses heritability enrichment to evaluate informativeness for disease. Heritability enrichment is defined as the proportion of heritability explained by SNPs in an annotation divided by the proportion of SNPs in the annotation 11 ; this generalizes to annotations with values between 0 and 1 44 . We further define the Enrichment score (E-score) of a gene program as the difference between the heritability enrichment of the SNP annotation corresponding to the gene program of interest and the SNP annotation corresponding to a gene program assigning a probabilistic grade of 1 to all protein-coding genes with at least one enhancer-gene link in the relevant tissue (Methods). We use the p-value of the E-score as our primary metric, assessing statistical significance using a genomic block-jackknife as in our previous work 11 , because the p-values can be compared across datasets, whereas the E-score magnitude can vary substantially in gene programs dominated by a smaller (or larger) number of genes. We primarily focus on E-scores greater than 2, because E-scores that are statistically significant but small in magnitude may have more limited biological importance, as the cell types underlying these E-scores may be tagging other causal cell types. We performed this analysis over healthy cell type programs (data file S1), disease progression programs (data file S2), and cellular process programs (data file S3). We identified the top 50 genes driving disease enrichments with highest proximity based MAGMA (v 1.08) gene-disease association scores 39 of genes with high probabilistic grade in each gene program (Fig. 1C , data file S4, Methods) focusing on genes that are both (i) close to a GWAS signal and (ii) in an enriched gene program.

We analyzed a broad range of human scRNA-seq data, spanning 17 data sets from 11 tissues and 6 disease conditions. The 11 non-disease tissues include immune (peripheral blood mononuclear cells (PBMCs) 26, 45 , cord blood 27 , and bone marrow 27 ), brain 28 , kidney 46 , liver 47 , heart 25 , lung 29 , colon 34 , skin 48 and adipose 47 . The 6 disease conditions include multiple sclerosis (MS) brain 49 , Alzheimer's disease brain 30 , ulcerative colitis (UC) colon 34 , asthma lung 50 , idiopathic pulmonary fibrosis (IPF) lung 29 and COVID-19 bronchoalveolar lavage fluid 51 (Supplementary Fig. 1 ). In total, the scRNA-seq data includes 209 individuals, 1,602,614 cells and 256 annotated cell subsets (Methods, Supplementary Table 1) . We also compiled publicly available GWAS summary statistics for 60 unique diseases and complex traits (genetic correlation < 0.9; average N=297K) (Methods, Supplementary Table 2) . We analyzed gene programs from each scRNA-seq dataset in conjunction with each of 60 diseases and complex traits, but we primarily report those that are most pertinent for each program.

As a proof of principle, we benchmarked sc-linker by analyzing 5 blood cell traits that inherently correspond to underling cell types (Supplementary Table 2 ) using immune cell type programs constructed from scRNA-seq data (Fig. 2a,b, Supplementary Fig. 1) . We constructed 6 immune cell type programs that were identified across 4 data sets -two from PBMCs (k=4,640 cells; n=2 individuals 26 ; k=68,551; n=8 individuals 45 ), and one each of cord blood 27 (k=263,828; n=8) and bone marrow 27 (k=283,894; n=8). We identified the expected cell type enrichments, including enrichment of erythroid cells for red blood cell count, megakaryocytes for platelet count, monocytes for monocyte count, and of B cells and T cells for lymphocyte percentage (Fig. 2d,   Supplementary Fig. 2a) .

The Roadmap∪ABC enhancer-gene linking strategy outperformed every other enhancer-gene linking strategy we tested in identifying these expected enrichments, including its constituent Roadmap and ABC strategies, the standard 100kb window-based approach used in LDSC-SEG 18 ( Supplementary Fig. 3d,e) , other gene-proximal SNP-gene linking strategies such as exons and closest TSS at different genomic distances, other regulatory SNP-gene linking strategies using Promoter-capture Hi-C and eQTLs in GTEx whole blood, and combinations of these strategies ( Supplementary Fig. 3a,b and data file S5) . Additionally, the tissue-specific Roadmap∪ABCimmune enhancer-gene linking strategy generated slightly higher specificity of cell type enrichments compared to cell-type-specific enhancer-gene linking strategies, supporting the use of tissue-specific enhancer-gene linking (Supplementary Fig. 4l ). This trend may stem from existing cell-type-specific enhancer-gene links being noisier, due to the limited amount of underlying cell-type-specific data, or because tissue-specific enhancer-gene links may tag enhancer-gene links in causal cell types that were not assayed (distinct from tagging captured by cell type programs).

The cell type programs were robust to the number of cells and individuals. Specifically, cell type programs and their corresponding enrichment results were robust (correlation of r=0.91) to changes in the number of profiled cells for scRNA-seq datasets with greater than 500 cells ( Supplementary Fig. 4f-h) ; larger scRNA-seq datasets can uncover cell populations and states that may be missed in smaller datasets, due to sampling power. The cell type programs were also highly similar across different sets of individuals (r=0.96 on average between programs of the same cell type generated from different samples, with consistent specificity in expected enrichments; Supplementary Fig. 4i-k) .

We observed higher specificity of enrichments of relevant cell type-trait pairs for our polygenic approach based on specifically expressed genes vs. other cell types compared to several other approaches including (i) functional enrichment of fine-mapped SNPs 52 (Supplementary Fig. 5a) ;

(ii) all expressed genes in a cell type, defined across several thresholds (Supplementary Fig. 6 );

(iii) specifically expressed genes vs. other genes in the same cell type; or (iv) specifically expressed genes vs. other genes in the same cell type, after normalizing each gene across cell types ( Supplementary Fig. 7 and data file S6). We hypothesize that the "all expressed genes" approach greatly underperforms sc-linker because, for a given expressed gene, centrality of function in a cell is often reflected in its level of expression compared to that in other cells 53,54 .

Sc-linker also outperformed three methods that use the MAGMA software 39 . First, we considered a baseline method for scoring cell types by scoring each cell using MAGMA gene-level associations to a trait and averaging across all cells of a cell type. We scored each cell for a trait using the top 200 MAGMA genes with highest score for the trait, computing the average expression over all the genes and subtracting an expression-matched control gene set. Sc-linker generated higher cell type specificity in enrichments compared to this baseline ( Supplementary   Fig. 4n) . Second, sc-linker outperformed MAGMA gene set-level associations with a sensitivity/specificity index of 6.29 for sc-linker vs. 5.83 for MAGMA ( Supplementary Fig. 8 

and this was further underscored by a comparison across a broader set of cell types and diseases. Specifically, analyzing 3 major cell type categories (immune, brain, other) and 4 major categories of diseases (blood biomarkers, immune-related diseases, brain-related diseases, other diseases), and focusing on the most plausible pairings (immune cell types x blood biomarkers, immune cell types x immune-related diseases, and brain cell types x brain-related diseases), sc-linker attained a higher sensitivity/specificity index (9.47) compared to MAGMA (1.78) (Methods, Fig. 2c ). This is consistent with prior work showing that MAGMA can produce significant results in the absence of true enrichment (false positives) due to uncorrected genomic confounding (e.g., nongene set-specific exon enrichment), if no gene-level covariates are included to correct for potential confounding. Third, FUMA 35 , a web interface that applies (gene set-level) MAGMA with precompiled scRNA-seq data (distinct from the data in our study), underperformed both sc-linker and gene set-level MAGMA (data file S7 and S8).

We next analyzed 11 autoimmune and/or inflammation-associated diseases (Supplementary Table 2 ) using the 6 immune cell type programs above (Fig. 2a,b, Supplementary Fig. 1 ) and 10 (intra-cell type and inter-cell type) immune cellular process programs (Fig. 2f) . (Enrichment results for the remaining 49 diseases and traits with immune cell type programs are reported in Supplementary Fig. 9 ; we did not construct disease progression programs, as these datasets included healthy samples only). We identified cell type-disease enrichments that conform to known disease biology (Fig. 2e, Supplementary Fig. 2b) , including T cells for eczema 55, 56 , B and T cells for primary biliary cirrhosis (PBC) 18 , and dendritic cells and monocytes for Alzheimer's disease 57 . Additionally, the highly significant enrichments for MS across all 6 immune cell type programs analyzed are consistent with previous analyses 18, 58, 59, 60, 61 , supporting the validity of our approach.

Several of the significant cell type-disease enrichments are not as widely established and may implicate previously unexplored biological mechanisms (Fig. 2e, Table 1, Supplementary Fig.   2b ). For example, we detected significant enrichment in B cells for UC; B cells have been detected in basal lymphoid aggregates in the ulcerative colitis (UC) colon, but their pathogenic significance remains unknown 62 . In addition, T cells were highly enriched for celiac disease; the top driving genes including ETS1 (ranked 1), associated with T cell development and IL2 signaling 63 , and CD28 (ranked 3), critical for T cell activation. This suggests that aberrant T cell maintenance and activation may impact inflammation in celiac disease. Recent reports of a permanent loss of resident gamma delta T cells in the celiac bowel and the subsequent recruitment of inflammatory T cells may further support this hypothesis 64 . These results were recapitulated across an independent immune cell scRNA-seq dataset, both in the gene programs (average correlation: 0.78 for the same cell type) and disease enrichments (0.86 correlation of the E-score over all cell type and trait pairs). A cross-trait analysis of the patterns of cell type enrichments suggests that Celiac disease and rheumatoid arthritis involves cell-mediated adaptive immune response, UC and primary biliary cirrhosis involve antibody-mediated adaptive immune response, Alzheimer's disease has a strong signal of innate immune, and MS and IBD involve contributions from a wide range of immune cell types (Supplementary Fig. 10 ).

Analyzing the 10 immune cellular process programs (Fig. 2f ) across the 11 immune-related diseases and 5 blood cell traits, we identified both disease-specific enrichments and others shared across diseases (Fig. 2g, Table 1 ). For example, while T cells have been previously linked to eczema, we pinpointed higher enrichment in CD4 + T cells compared to CD8 + T cells. The IL2 signaling cellular process program in T and B cells was significantly enriched for both eczema and celiac disease, though the genes driving the enrichment were not significantly overlapping (pvalue: 0.21). Additionally, the complement cascade cellular process program in plasma, B, and hematopoietic stem cells (HSCs) was most highly enriched among all inter cellular programs for celiac disease. For Alzheimer's disease, there was a strong enrichment in both classical and nonclassical monocyte intra-cell type cellular programs, and in MHC class II antigen presentation (inter cell type; dendritic cells (DCs) and B cells) and prostaglandin biosynthesis (inter cell type; monocytes, DCs, B cells and T cells) programs. Among the notable driver genes were: IL7R (ranked 1) and NDFIP1 (ranked 3) for CD4 + T cells in eczema, which respectively play key roles in Th2 cell differentiation 65, 66 and in mediating peripheral CD4 T cell tolerance and allergic reactions 67, 68 ; and CD33 (ranked 1) in MHC class II antigen processing in Alzheimer's disease, a microglial receptor strongly associated with increased risk in previous GWAS 69, 70 .

We next focused on brain cells and psychiatric disease, by analyzing 9 cell type programs ( Fig.   3a ) and 12 cell process programs (Fig. 3e , 10 intra-and 2 inter-cell type programs) from scRNAseq data of brain prefrontal cortex (k=73,191, n=10) 28 Table 2 ). We did not construct disease progression programs, as this dataset included healthy samples only.

Notably, we observed enrichments of major depressive disorder (MDD) and body mass index (BMI) specifically in GABAergic neurons, while insomnia, schizophrenia (SCZ), and intelligence were highly enriched specifically in glutamatergic neurons, and neuroticism was highly enriched in both. GABAergic neurons regulate the brain's ability to control stress levels, which is the most prominent vulnerability factor in MDD 71 (Fig. 3b ,c, Table 1 , Supplementary Fig. 2c) . Among the top genes driving this enrichment were TCF4 (ranked 1), a critical component for neuronal differentiation that affects neuronal migration patterns 72, 73 , and PCLO (ranked 4), which is important for synaptic vesicle trafficking and neurotransmitter release [74] [75] [76] . Although predominant therapies for MDD target monoamine neurotransmitters, especially serotonin, the enrichment for GABAergic neurons is independent of serotonin pathways, suggesting that they might include new therapeutic targets for MDD. These results were robustly detected in an independent brain scRNAseq dataset, both in the gene programs (average correlation: 0.77 for the same cell type and -0.21 otherwise) and disease enrichments (0.77 correlation of the E-score over all cell type and trait pairs), including GABAergic neurons in MDD and BMI as well as glutamatergic neurons in insomnia and SCZ. Enrichment results for the remaining 49 diseases and traits in conjunction with brain cell type programs are reported in Supplementary Fig. 9 .

Tissue specificity of both the cell type program and enhancer-gene strategy was important for successful linking, which we found by comparing the enrichment of all four possible combinations of immune or brain cell type programs with immune-or brain-specific enhancer-gene linking strategies, meta-analyzed across 11 immune-related diseases or 11 psychiatric/neurological diseases and traits (Fig. 3d) . This highlights the importance of leveraging the tissue specificity of enhancer-gene strategies.

The 12 brain cellular process programs showed that the significant enrichment of brain-related diseases in neuronal cell types above is primarily driven by finer programs reflecting neuron subtypes (Fig. 3f, Table 1 , Supplemental Note). For example, the enrichment of GABAergic neurons for BMI was driven by programs reflecting LAMP5 + and VIP + subsets. Furthermore, the enrichment of GABAergic neurons for MDD reflects SST + and PVALB + subsets. We also observed enrichment in more specific cell subsets within glutamatergic neurons (e.g. IT neurons were enriched for neuroticism). Among inter cell type programs, electron transport cellular process programs (GABAergic and glutamatergic neurons) were enriched for several psychiatric/neurological traits, such as years of education, consistent with previous studies 77 .

Analysis of kidney, liver, heart, skin and adipose cell types (Supplementary Table 1 ) and corresponding relevant traits (Supplementary Table 2 ) revealed the role of particular immune, stromal and epithelial cellular compartments across different diseases/traits. For example, kidney and liver cell type programs (Supplementary Fig. 1 ) highlighted relations with urine biomarker traits (Fig. 4a, Supplementary Fig. 9 and 11a,b) , such as enrichment for creatinine level in kidney proximal and connecting tubule cell types, but not in liver cell types, as expected 78,79 , or a significant enrichment for bilirubin level only in liver hepatocytes (driven by ANGPTL3; ranked 4) 80,81 . In heart (Fig. 4B, Supplementary Fig. 9 and 11c, Table 1 ), atrial cardiomyocytes were enriched for atrial fibrillation, and pericyte and smooth muscle cells for blood pressure, consistent with their respective roles in determining heart rhythm through activity 82 of ion channels (top genes included the ion channel genes PKD2L2 (ranked 2), CASQ2 (ranked 7) and KCNN2 (ranked 18)) and blood pressure regulation through vascular tone 83 (top genes driving included adrenergic pathway genes PLCE1 (ranked 1), CACNA1C (ranked 21), and PDE8A (ranked 23)). In skin (Fig.   4c , Supplementary Fig. 9 , Table 1 

We expanded our analysis to evaluate all cell type programs for all diseases/traits, irrespective of the tissue locus of disease aiming to identify cell type enrichments involving "mismatched" cell type -disease/trait pairs (Supplementary Figure 5) . As expected, in most cases "mismatched" cell type programs and disease/trait pairs do not yield significant association. Notable exceptions included enrichments of skin Langerhans cells for Alzheimer's disease (AD) (E-score: 15.2, p=10 -4 ), M cells (in colon) for asthma (E-score: 2.2, p=10 -4 ), and heart smooth muscle cells for lung capacity (E-score: 5.6, p=3*10 -4 ).

In some cases, the association may indicate a direct relationship, whereas in other cases the associated cell type may only "tag" the causal cell type in the disease tissue, as cell type programs derived from cells of the same type across tissues were found to be highly correlated ( Fig. 4e) with consistent enrichment in these correlated cell type programs ( Supplementary Fig. 5 and 9 ). The enrichment of Langerhans cells for AD is plausible given that Langerhans cells respond differently to Ab peptides, which has implications in AD immunotherapy 89 . On the other hand, the enrichment of colon M cells for asthma may suggest a role for lung-resident M cells, which have not been identified to date but are expected to be in the lung, as M cells stimulate IgA antibody production as an immune response 90 , while selective IgA immunodeficiency increases risk for asthma 91 .

Similarly, the heart smooth muscle cell program may merely mirror that of airway smooth muscle cells, whose function is a pivotal determinant of lung capacity 92 .

We next turned to cases where both healthy and disease tissue have been profiled, allowing us to identify heritability in programs associated with disease-specific biology. Such understanding is especially important for identifying therapeutic targets associated with disease progression rather than disease onset mechanisms.

We first examined disease progression programs in multiple sclerosis (MS) and Alzheimer's disease (AD) , where aberrant interactions between neurons and immune cells are thought to play an important role. We analyzed MS and AD GWAS data (Supplementary Table 2 ) along with cell type, disease progression, and cellular process programs from scRNA-seq of healthy and MS 49 or AD 30 brain (Fig. 5a ,e, Supplementary Table 1) . We considered brain enhancer-gene links (since MS and AD are neurological diseases), immune enhancer-gene links (since MS and AD are immune-related diseases) and non-tissue-specific enhancer-gene links (Supplementary Fig. 12) and detected strongest enrichment results for the immune enhancer-gene links. In both MS and AD, disease progression programs in each cell type differed substantially from cell type programs constructed from cells from healthy (r=0.16) or disease (r=0.29) samples alone ( Supplementary   Fig. 13 ). Furthermore, we confirmed that disease GWAS matched to the corresponding disease progression programs produced the strongest enrichments, although there was substantial crossdisease enrichment (Supplementary Fig. 14) .

In MS, there was enrichment in disease progression programs in GABAergic neurons and microglia ( Fig. 5b, Supplementary Fig. 15 ), as well as in Layer 2,3 glutamatergic neurons and the complement cascade (in multiple cell types) (Fig. 5d) . The specific enrichment of the GABAergic neuron disease progression program (but not the healthy cell type program) for MS is consistent with the observation that inflammation inhibits GABA transmission in MS 94 . The GABAergic disease progression program was enriched with hydrogen ion transmembrane transporter activity genes, while the GABAergic cell type program was enriched in genes with general neuronal functions (data file S9). The enrichment of the microglia disease progression for MS is consistent with the role of microglia in inflammation and demyelination in MS lesions 95, 96 and highlights a contribution of microglia in both disease onset and response. The top driving genes for the microglia disease progression enrichment included MERTK (ranked 2) and TREM2 In AD, all associations highlighted the central role of microglia, suggesting that different processes may be at play at microglia or microglia subsets in healthy brain and after disease initiation: only the microglia disease progression program was enriched out of 8 disease progression programs tested ( Fig. 5e,f, Supplementary Fig. 16) , along with the healthy microglia program, and the apelin signaling pathway disease-specific cellular process program (inter cell type; GABAergic neurons and microglia). The microglia program enrichments are consistent with the contribution of microglia-mediated inflammation to AD progression 102, 103 . The top genes driving enrichment specifically in the disease progression program (but not the healthy cell type program) included PICALM1, APOC1, APOE and TREM2 (ranked 1, 2, 3 and 8). APOE regulates microglial responses to Alzheimer's related pathologies [104] [105] [106] , APOC1 is a an APOE-dependent suppressor of glial activation 107 , and TREM2 modulates microglial morphology and neuroinflammation in Alzheimer's disease pathogenesis models 108, 109 . Supporting this finding, there is a significant increase in the number of microglia in AD brain (Fig. 5g, data file S10) . The apelin signaling pathway disease-specific cellular process program is consistent with recent studies implicating this pathway in reducing neuroinflammation in animal models of Alzheimer's disease 110, 111 . The top genes driving the enrichment included SORL1 and SYK (ranked 2 and 3). SORL1 expression levels are significantly reduced in Alzheimer's disease patients, and has also been implicated by rare variant analyses [112] [113] [114] .

Thus, in both MS and AD, heritability was enriched in distinct ways in microglia cell type, disease progression and cellular process programs, suggesting new therapeutic opportunities to combat the role of microglia in varying contexts for disease risk and highlighting the importance of a multifaceted analysis.

We next examined the role of cell type, disease progression and cellular process programs in ulcerative colitis (UC), where failure to maintain the colon's epithelial barrier results in chronic inflammation. We analyzed UC and IBD GWAS data (Supplementary Table 2 ) with healthy cell type, UC disease progression and UC cellular process programs constructed from scRNA-seq from healthy colon, and from matched uninflamed and inflamed colon of UC patients (Fig. 6a, Supplementary Table 1) . We compared colon enhancer-gene links (Fig. 6) and non-tissue-specific enhancer-gene links (Supplementary Fig. 12 ) and detected strongest enrichment results for the colon enhancer-gene links. As in MS and AD, UC disease progression programs in each cell type differed substantially from corresponding healthy or disease colon cell type programs (average Pearson r=0.24; Supplementary Fig. 13 , data file S11).

In addition to previously observed enrichments in healthy immune cell type programs, our analysis highlighted healthy cell type programs of enteroendocrine and endothelial cells, disease progression programs of enterocytes and M cells, as well as the complement cascade (in plasma, B cells, enterocytes and fibroblasts), MHC-II antigen presentation (macrophages, monocytes and dendritic cells), and EGFR1 signaling (macrophages and enterocytes) in both healthy and disease cells (Fig. 6, Supplementary Fig. 9 , data file S1). The strong enrichment in endothelial cells, which comprise the gut vascular barrier, is consistent with their rapid changes in UC 115 ; the top driving genes included members of the TNF-" signaling pathway (EFNA1, NFKBIA, CD40, ranked 18, 26, 29), a key pathway in UC 116 .

The disease progression programs (Fig. 6c, Table 1, Supplementary Fig. 15 and 11 ) highlighted M cells, a rare cell type in healthy colon that increases in UC 34 (Fig. 6d , data file S10). M cells surveil the lumen for pathogens and play a key role in immune-microbiome homeostasis 117 .

Supporting this finding, mutations in FERMT1, a top driving gene in the M cell disease progression program (ranked 3), cause Kindler syndrome, a monogenic form of IBD with UC-like symptoms [118] [119] [120] . Notably, there was no enrichment in M cell healthy cell type programs (Fig. 6b) , emphasizing that M cells are activated specifically in UC disease, as their proportions increase (p=0.008) (Fig. 6d) .

We analyzed GWAS data for asthma, IPF, COVID-19 (both general COVID-19 and severe , and lung capacity (Supplementary Table 2 ) with healthy cell type, disease progression and cellular process programs from asthma, IPF, COVID-19 and healthy 29 (lower lung lobes) tissue scRNA-seq (Fig. 7a,c,f, Supplementary Fig. 13d-f and 15 , data file S11), using either lung enhancer or immune enhancer gene links. For asthma, there was significant enrichment for healthy cell type and disease progression programs in T cells (see Supplemental Note), and for lung capacity (height-adjusted FEV1adjRVC), there was significant enrichment for healthy cell type and disease progression programs in fibroblasts (Fig. 7b , data file S1) and the MAPK cellular process program (in basal, club, fibroblast and endothelial cells) (Fig. 7f, g, Table 1 ). For IPF and COVID-19, the enrichment results are detailed in the Supplemental Note.

For example, both healthy and disease progression fibroblast/stromal programs were enriched for lung capacity (but not asthma), consistent with the adverse impact of overproduction of extracellular matrix (ECM) on the reduced lung capacity and elasticity characteristic of fibrosis 121 .

In the cell type program, top driving genes included LOX (ranked 1), which alters ECM mechanical properties via collagen cross-linking 122 , and TGFBR3 (ranked 37) which regulates the pool of available TGFb, a master regulator of lung fibrosis. Notably, the enrichment of basal cell disease progression programs, but not healthy cell type programs, in lung capacity are supported by the significant increase (p-value: 3x10 -5 ) in basal cells in asthma vs. healthy lungs (Fig. 7e) . Expanding the analysis to cellular process programs, the top driving genes of the enrichment of a MAPK signaling pathway program for lung capacity (in basal, club, fibroblast and endothelial), include FOXA3 (ranked 1), which plays a key role in allergic airway inflammation 123 , and PDE2A (ranked 2), which has been associated with alveolar inflammation 124 .

Prior work on identifying disease-critical tissues and cell types by combining expression profiles and human genetics signals has largely focused on the direct mapping of the expression of individual genes 34 and genome-wide polygenic signals 18, 36 to discrete cell categories. Our study demonstrates that there is much to be gained by linking inferred representations of the underlying biological processes beyond cell types in different cell and tissue contexts with genome-wide polygenic disease signals, by integrating scRNA-seq, epigenomic and GWAS data sets.

Our work introduces three main conceptual advances. First, by integrating scRNA-seq data and GWAS summary statistics using tissue-specific enhancer-gene linking strategies, we detect subtle differences in SNP to gene mapping between tissues which upon aggregation over the full GWAS signal produce strong differences in disease heritability across cell types. Second, by constructing disease progression programs comparing cells of the same type in disease vs. healthy tissue, we project GWAS signals across disease-specific cell states. Third, by using NMF to construct cellular process programs that do not rely on known cell type categories, we identify cellular mechanisms that vary across a continuum of cells of one type or are shared between cells of different types such as the MAPK signaling pathway identified in the lung.

Leveraging these advances, we identified notable enrichments ( Table 1 ) that have not previously been identified using GWAS data and are biologically plausible but not clearly expected, thus providing important new knowledge. We also observed patterns across datasets that offer new insights. For example, we observed that disease progression programs, but not healthy cell type

(UC and asthma). In contrast, for immune cells healthy and disease progression programs tended to be similarly enriched. We posit that this suggests a role for epithelial cells in disease progression over initiation. Future studies are required to experimentally validate these new hypotheses.

Our work has several limitations that highlight directions for future research. First, the enhancergene linking strategies from Roadmap and Activity-By-Contact (ABC) models are limited in the tissues and cell states represented. More fine-grained enhancer-gene linking strategies will likely prove beneficial, but the strategies that we used here provide a clear improvement over a standard gene window-based approach. Second, we focus on genome-wide disease heritability (rather than a particular locus); however, our approach can be used to implicate specific genes and gene programs. Third, sc-linker does not distinguish whether two cell types (or more generally, gene programs) implicated in disease exhibit conditionally independent signals. Assessing this via a conditional S-LDSC analysis of the corresponding SNP annotations is likely to be underpowered, as the gene programs (and SNP annotations) may be highly correlated. A more powerful approach may be to define cell type programs based on specific expression relative to a narrower set of cells.

Fourth, although all studies considered in this work profiled large numbers of cells (up to 300,000 in some tissues), some rare cell types and processes may not yet be adequately sampled due to the number of cells or their tissue distribution 125 , or may only be apparent in a disease context, as we observe for rare M cells in UC. Fifth, we have focused on human scRNA-seq data 33 ; however, incorporating data from animal models, as discussed in prior work 36 , would allow experimental validation of disease mechanisms in model organisms. Sixth, the disease progression programs that we link to disease may not be causal for disease, but rather reflect disease-induced changes or genetic susceptibility to disease 126, 127 . However, our findings clearly validate the relevance of these gene programs to disease as observed in M cells and UC 34 . Seventh, the LD score regression framework 11 is primarily applicable to common and low-frequency variants, and less applicable to rare variant enrichments. Eighth, we capture programs by cell category or gene co-variation, whereas future work could extend beyond these to capture dynamic cellular transitions 128 .

Looking forward, the gene program-disease links identified by our analyses can be used to guide downstream studies, including designing systematic perturbation experiments 129, 130 in cell and animal models 131 for functional follow up. We anticipate that gene programs will continue to grow and refine due to the continued growth of different types of profiling data -including from singlecell atlases across many tissues and diseases, Perturb-seq 129 experiments under genetic or chemical perturbation, spatial transcriptomics, and other modalities 132, 133 . Such analyses can then expand to genetic interactions within and between cells. In the long term, with the increasing success of PheWAS and the integration of multi modal single cell resolution epigenomics, this framework will continue to be useful in identifying biological mechanisms driving a broad range of diseases.

All scRNA-seq datasets in this study [25] [26] [27] [28] [29] [30] 34 ,45-51 are publicly available cell by gene expression matrices that are aligned to the hg38 human transcriptome (Supplementary Table 1) . Each dataset included metadata information for each cell describing the total number of reads in the cell and which sample the cell corresponds to and, if applicable, its disease status. We transformed each expression matrix to a count matrix by reversing any log normalization processing (because each downloaded dataset contained either (i) raw counts, (ii) normalized log2 TP10K, or (iii) normalized log10 TP10K), and standardized the normalization approach across all datasets to account for differences in sequencing depth across cells by normalizing by the total number of UMIs per cell, converting to transcripts-per-10,000 (TP10K) and taking the log of the result to obtain log(10,000*UMIs/total UMIs + 1) "log2(TP10K+1)" as the final expression unit.

The log2(TP10K+1) expression matrix for each dataset was used for the following downstream analyses. For each dataset, we identified the top 2,000 highly variable genes across the entire dataset using Scanpy's 42 highly_variable_genes function with the sample ID as input for the batch. 136 . If prior annotations were available they are used as a reference to annotate each cell in each dataset. If prior annotations were not available, we used established cell type-specific expression signatures and gene markers described in the data source to annotate cells at the resolution of Leiden clusters.

We constructed cell type programs for every cell type in a given tissue by applying a nonparametric Wilcoxon rank sum test for differential expression (DE) between each cell type vs.

other cell types and computed a p value for each gene. Using a previously published strategy 15 , we transform these p-values to X = -2 log (p), which follow a # ! ! distribution, and these transformed values to a grade between 0 and 1 using the min max normalization g = ( X -min (X) )/( max(X)

-min(X) ) resulting in a relative weighting of genes in each program. In brief, cell type programs constructed from healthy cells were termed as healthy cell type programs and similarly cell type programs constructed from disease cells were termed as disease cell type programs.

We constructed disease progression programs for each cell type observed in both healthy and matching disease tissue. For each cell type, we computed a gene-level non-parametric Wilcoxon rank sum DE test between cells from healthy and disease tissues of the same cell type. The pvalues for each gene were transformed to a grade between 0 and 1 using the same strategy as in the cell type program to form a relative weighting of genes in each program. In the COVID-19

BAL scRNA-seq, we also constructed viral progression programs based on differential expression between viral infected and uninfected cells of the same cell type in COVID-19 disease individuals.

We observed low correlation between healthy cell type gene programs and disease progression gene programs (see Supplementary Fig. 13 and data file S11).

Using it as an 'intra-cell type' or 'inter-cell type' cellular process program if highly correlated with only one or multiple cell type programs, respectively.

For scRNA-seq from healthy and disease tissue contexts, we propose a modified NMF approach to construct gene programs that are either shared across both tissues, specific to healthy tissue or specific to disease tissue. Let 4 * * , ! be the observed gene expression data for a tissue > from a healthy individual and ? * * , " be the observed gene expression data for the corresponding tissue from a disease individual. @ is the number of features (genes) and A ) and A ! denote the number of samples from the healthy and disease tissues, respectively.

We assume a non-negative matrix factorization for 4 and ? as follows

where L / is the number of shared programs between the healthy and the disease samples, L 0 is the number of healthy specific programs and L 5 is the number of disease-specific programs. D /0 and D /5 are used to denote the shared programs between healthy and disease states. Therefore, we assume that D /0 is very close to D /5 but not exact to account for other factors like experimental conditions perturbing the estimates slightly. On the other hand, D 10 and D 15 are used to denote the healthy-specific and disease-specific programs respectively. F 0 $)M F 5 denote the program weights in the healthy and disease samples respectively. frame this in the form of the following optimization problem

Where To determine the multiplicative updates of the NMF optimization problem in Equation 4 we compute the derivatives of the optimization criterion with respect to each parameter of interest.

We call the optimization criterion as Y:

Following the multiplicative update rules of NMF as per Lee and Seung (NIPS 2001), we get the following iterative updates and assume convergence has been achieved after 100 iterations or when the reconstruction error is below a user-specified error threshold (here the threshold is taken to be 1e-04).

We define an enhancer-gene linking strategy as an assignment of 0, 1 or more genes to each SNP with a minor allele count >5 in the 1000 Genomes Project European reference panel 137 of genes expressed in the scRNA-seq were observed to have enhancer-gene links. We also consider non-tissue specific Roadmap and ABC strategies (Supplementary Fig. 12) . Besides this enhancergene linking strategy, we also considered a standard 100kb window-based strategy 13, 18 .

We define an annotation as an assignment of a numeric value to each SNP in a predefined reference 

Stratified LD score regression (S-LDSC) assesses the contribution of a genomic annotation to disease and complex trait heritability 11 . S-LDSC assumes that the per-SNP heritability or variance of effect size (of standardized genotype on trait) of each SNP is equal to the linear contribution of each annotation.

:$%_ß 8`= 1 $ 89

where ajc is the value of annotation c at SNP j, with the annotation either continuous or binary is the stratified LD score of SNP j with respect to annotation c, % 8; is the genotypic correlation between SNPs j and k computed using 1000 Genomes Project, and N is the GWAS sample size.

We assess the informativeness of an annotation c using two metrics. The first metric is Enrichment score (E-score), which relies on the enrichment of annotation c (b 9 ), defined for binary annotations as follows (for binary and probabilistic annotations only): 

where iM 9 is the standard error of annotation c, ℎ < ! is the total SNP heritability and M is as defined previously. h 9 * is the proportionate change in per-SNP heritability associated with an increase of one standard deviation in the value of a annotation.

We assessed the statistical significance of the enrichment score and h * via block-jackknife, as in previous work 11 , with significance thresholds determined via False Discovery Rate (FDR) correction (q-value < 0.05) 140 . FDR was calculated over all relevant relatively independent traits for a tissue and all programs of a particular type (cell type programs, disease progression programs, cellular process programs) derived from that tissue. We used the p-value for nonzero enrichment score as our primary metric, because h * is often non-significant for small cell-type-specific annotations when conditioned on the baseline-LD model 141 .

We analyzed publicly available GWAS summary statistics for 60 unique diseases and traits with genetic correlation less than 0.9. Each trait passed the filter of being well powered enough for heritability studies (z score for observed heritability > 5). We used the summary statistics for SNPs with minor allele count >5 in a 1000 Genomes Project European reference panel 137 

We define a sensitivity/specificity index to benchmark (i) sc-linker vs. MAGMA gene-set Fig. 4e , the putatively positive control combinations include immune programs for blood cell traits and immune diseases, and brain programs for brain related traits; all other combinations are considered to be putatively negative controls. In Supplementary Fig. 8 Fig. 6 and 7) or different ways to link SNPs to genes beyond Roadmap∪ABC enhancer-gene linking strategy (Fig. 3d,e and Supplementary   Fig. 3 ), we use a slightly different definition of sensitivity/specificity index. Instead of the -log Pvalue, we use the t* metric from the S-LDSC method, which evaluates conditional information in the SNP annotation corresponding to a gene program, corrected for the annotation size. This metric is preferred when comparing across cell-type programs or enhancer-gene linking strategies that are widely different in their corresponding SNP annotation sizes, as is the case in these comparisons (we note that use of this metric is not possible in comparisons involving MAGMA, which does not estimate t*).

For each gene program, we first subset the full gene list to only consider genes with greater than 80% probability grade of membership in the gene program. Subsequently, we ranked all remaining genes using MAGMA (v 1.08) gene level significance score and considered the top 50 ranked genes for further downstream analysis, which is different from the top 200 genes used for a "baseline" method for scoring cell type enrichments for disease that we used as a benchmark for sc-linker.

To identify changes in cell type proportions between healthy and disease tissue, we used a multinomial regression test to jointly test changes across all cell types simultaneously. This helps account for all cell type changes simultaneously, as an increase in the number of cells of one cell types implies fewer cells of the other cell type will be captured. This regression model and the associated p-values were calculated using the multinom function in the nnet R package.

All postprocessed scRNA-seq data (except for Alzheimer's disease; see below), gene programs, 

We thank Leslie Gaffney for assistance with preparing figures as well as Sijia Chen, Chris Smillie, 

A.R. is a co-founder and equity holder of Celsius Therapeutics, an equity holder in Immunitas, and was an SAB member of ThermoFisher Scientific, Syros Pharmaceuticals, Neogene Therapeutics and Asimov. From August 1, 2020, A.R. is an employee of Genentech. Table 1 . Notable enrichments from analyses of cell type, disease progression and cellular process gene programs. For each notable enrichment, we report the GWAS disease/trait, tissue source for scRNA-seq data, cell type, enrichment score (E-score), 1-sided p-value for positive E-score, and top genes driving the enrichment. Nominally significant enrichments for diseases with limited GWAS sample size are colored in grey. MDD is an abbreviation for major depressive disorder, blood pressure (dia.) is an abbreviation for diastolic blood pressure, mac-neutrophil trans. is an abbreviation for macrophage-neutrophil transition. * denotes cellular process programs 56 shared across healthy and disease states. ** denotes cellular process programs specific to disease states. The full list of genes driving these associations is provided in data file S4. Figure 1 . program memberships for immune cell type programs across different tissues (rows, columns), grouped by cell type (labels). Supplementary Fig. 9 and data file S1. c. Enrichments of UC disease progression programs for disease. Magnitude (Escore, dot size) and significance (-log10(P-value), dot color) of the heritability enrichment of UC disease progression programs (columns) for IBD or UC (rows). d. Proportion (mean and SE) of the corresponding cell types (columns) in healthy (blue) and UC (red) colon samples. P-value: Supplementary Fig. 4 . Benchmarking sc-linker across immune cell type programs and blood cell traits. a-c. Magnitude (E-score, dot size) and significance (-log10(P-value), dot color) of the heritability enrichment of immune cell type programs (columns) aggregated over 4 scRNA-seq datasets (PBMC (2), cord blood, and bone marrow) for 5 blood cell traits with SNP annotations combined with 100Kb (a), ABC-immune (b) or Roadmap-immune (c) strategies (compare to Roadmap∪ABC-immune strategy in Fig. 2b) . d,e. Mean E-score (d) or average standardized effect size (! * ) (e) (y axis) for blood cell traits and immune cell type programs as in Fig. 2b , with SNP annotations combined with 100Kb, ABC-immune, Roadmap-immune or Roadmap∪ABCimmune strategy (x axis). Errors bars: 95% confidence intervals. f. Pairwise correlation heat map between all cell type programs computed for each sample separately. g. Magnitude (E-score, dot size) and significance (-log10(P-value), dot color) of the heritability enrichment of immune cell type programs constructed for each sample. h. Specificity index (y axis; see Methods) for immune cell type programs generated from each individual. i. Pairwise correlation heat map between all cell type programs computed for each dataset size separately. j. Magnitude (E-score, dot size) and Enrichment in blood cell traits for binary and regular cell type programs. Enrichment (E score, dot size; and significance (-log10(P-value), dot color) for blood cell traits (rows) with cell type program defined by genes expressed in more than 10% of cells (a) or by our regular approach (b, as in Fig. 2d) . The size of each corresponding SNP annotation (% of SNPs) is reported in parentheses. c. Regular cell type programs have a higher specificity than dichotomous ones. Specificity index metric (y axis, mean and s.e.) for blood biomarker and immune cell type programs defined by our regular approach ("cell type") or by genes expressed in more than 10, 30 or 50% of cells of a given type (x axis). Numerical results are reported in data file S6. 

Extended analysis of disease critical brain cellular processes

The 12 brain cellular process programs showed that the significant enrichment of neuronal cell types above is primarily driven by finer programs reflecting neuron subtypes (Fig. 3f, Table 1 ).

For example, the enrichment of GABAergic neurons for BMI was driven by programs reflecting LAMP5 + and VIP + subsets; the respective top driving genes included FLRT1 (for LAMP5 + neurons; ranked 1), whose absence reduces intercellular adhesion and promotes premature neuron migration 147 , and TIMP2 (for VIP + neurons; ranked 7), implicated in obesity through hypothalamic control of food intake and energy homeostasis in mice 148, 149 . Furthermore, the enrichment of GABAergic neurons for MDD reflects SST + and PVALB + subsets; the respective top driving genes included PCLO (for SST + GABAergic neurons; ranked 2), and ADARB1 (for PVALB + neurons; ranked 4), encoding an RNA editing enzyme that can edit the transcript for the serotonin receptor 2C with a role in MDD 150 . We also observed enrichment in more specific cell subsets within the glutamatergic neurons (IT neurons were enriched for neuroticism, whereas L6 neurons were enriched for years of education and intelligence). Among inter cell type programs, electron transport cellular process programs (GABAergic and glutamatergic neurons) were enriched for several psychiatric/neurological traits, such as years of education, consistent with previous studies 77 , with the top driving genes including ATP6V0B and NDUFAF3 (ranked 1, 4).

For example, healthy cell type and disease progression T cell programs were enriched in asthma, consistent with the contribution of T cell-driven inflammation to airway hyper-responsiveness and tissue remodeling 151 . From a pathway enrichment analysis, we identified that healthy T cell program overlapped with T cell receptor signaling, while the T cell disease progression program overlapped with RNA binding (see data file S9). These partially overlapping programs both included IL2 signaling pathway genes; IL2 is a T cell growth factor that increases airway response to allergens 152 and drives differentiation of Th2 cells linked to asthma 153 .

For IPF, a disease characterized by mucociliary dysfunction 154 , the mucous disease progression program was most enriched, and nominally significant (p = 0.04, not FDR significant), with top driving genes including DSP (ranked 1), a cell-cell adhesion molecule linked to tissue architecture in IPF lung 155 , and MUC5B (ranked 2), the well characterized genetic risk factor for IPF that likely increases mucinous expression in terminal airways of the lung 154 .

For severe COVID-19 156 , the macrophage disease progression program was enriched, and nominally significant (p = 0.01, not FDR significant), with top driving genes including key antiviral enzyme activators 157,158 OAS3 and OAS1 (ranked 1, 3), and CCR5, a chemokine receptor in which therapeutic intervention has been associated with improved prognosis in severe COVID-19 patients 159 . Further analyses of a meta-atlas of COVID-19 scRNA-seq in conjunction with COVID-19 GWAS data are described elsewhere 160 . Our nominally significant findings should be interpreted cautiously, but should become more powered as IPF and COVID-19 GWAS sample sizes grow.

Biological Insights From 108 Schizophrenia-Associated Genetic Loci

10 Years of GWAS Discovery: Biology, Function, and Translation

The NHGRI-EBI GWAS Catalog of published genome-wide association studies, targeted arrays and summary statistics 2019

Systematic Localization of Common Disease-Associated Variation in Regulatory DNA

Progress and promise in understanding the genetic basis of common diseases

Genomic medicine --progress, pitfalls, and promise

Translational genomics and precision medicine: Moving from the lab to the clinic

Mechanisms of tissue and cell-type specificity in heritable traits and diseases

Chromatin marks identify critical cell types for fine mapping complex trait variants

Joint Analysis of Functional Genomic Data and Genome-wide Association Studies of 18 Human Traits

Partitioning heritability by functional annotation using genome-wide association summary statistics

Deep learning sequence-based ab initio prediction of variant effects on expression and disease risk

Large-scale genome-wide enrichment analyses identify new traitassociated genes and pathways across 31 human phenotypes

A Bayesian framework that integrates multi-omics data and gene networks predicts risk genes from schizophrenia GWAS data

A genetics-led approach defines the drug target landscape of 30 immunerelated traits

Inferring Relevant Cell Types for Complex Traits by Using Single-Cell Gene Expression

Estimating the causal tissues for complex traits and diseases

Heritability enrichment of specifically expressed genes identifies disease-relevant tissues and cell types

Systematic analysis of chromatin state dynamics in nine human cell types

Integrative analysis of 111 reference human epigenomes

Evidence of reduced recombination rate in human regulatory domains

Activity-by-Contact model of enhancer-promoter regulation from thousands of CRISPR perturbations

Genome-wide maps of enhancer regulation connect risk variants to disease genes

Scaling single-cell genomics from phenomenology to mechanism

Transcriptional and Cellular Diversity of the Human Heart

A molecular cell atlas of the human lung from single cell RNA sequencing

Census of Immune Cells (Human Cell Atlas)

Allen Brain Atlas: an integrated spatio-temporal portal for exploring the central nervous system

Single-cell RNA sequencing reveals profibrotic roles of distinct epithelial and mesenchymal lineages in pulmonary fibrosis

Single-cell transcriptomic analysis of Alzheimer's disease

A Cancer Cell Program Promotes T Cell Exclusion and Resistance to Checkpoint Blockade

A revised airway epithelial hierarchy includes CFTR-expressing ionocytes

Molecular Classification and Comparative Taxonomics of Foveal and Peripheral Cells in Primate Retina

A single-cell survey of the small intestinal epithelium

Regulation of T Cell Immunity in Atopic Dermatitis by Microbes: The Yin and Yang of Cutaneous Inflammation

Skin-Infiltrating CD8+ T Cells Initiate Atopic Dermatitis Lesions

The dynamics of monocytes and microglia in Alzheimer's disease

Dendritic cells in multiple sclerosis: key players in the immunopathogenesis, key players for new cellular immunotherapies?

Expansion of Neutrophils and Classical and Nonclassical Monocytes as a Hallmark in Relapsing-Remitting Multiple Sclerosis

Evidence of platelet activation in multiple sclerosis

Fingolimod and changes in hematocrit, hemoglobin and red blood cells of patients with multiple sclerosis

Characterisation of mucosal lymphoid aggregates in ulcerative colitis: immune cell phenotype and TcR-γδ expression

The Ets-1 transcription factor controls the development and function of natural regulatory T cells

Chronic Inflammation Permanently Reshapes Tissue-Resident Immunity in Celiac Disease

Cloning of a receptor subunit required for signaling by thymic stromal lymphopoietin

Genetic Variants in TSLP are Associated with Atopic Dermatitis and Eczema Herpeticum

Ndfip1 mediates peripheral tolerance to self and exogenous antigen by inducing cell cycle exit in responding CD4+ T cells

The Nedd4-2/Ndfip1 axis is a negative regulator of IgE-mediated mast cell activation

Microglial genes regulating neuroinflammation in the progression of Alzheimer's disease

Late onset Alzheimer's disease genetics implicates microglial pathways in disease risk

The GABAergic Deficit Hypothesis of Major Depressive Disorder

The importance of TCF4 gene in the etiology of recurrent depressive disorders

Disruption of TCF4 regulatory networks leads to abnormal cortical development and mental disabilities

PCLO gene: its role in vulnerability to major depressive disorder -PubMed

The PCLO gene and depressive disorders: replication in a population-based study

Genome-Wide Significance for PCLO as a Gene for Major Depressive Disorder

Mitochondrial dysfunction and psychiatric disorders

Proximal Tubular Secretion of Creatinine by Organic Cation Transporter OCT2 in Cancer Patients

Tubular secretion of creatinine and kidney function: an observational study

Hepatic uptake of bilirubin and its conjugates by the human organic anion transporter SLC21A6

Bilirubin metabolism: Applied physiology

Cardiac metabolism and arrhythmias

Tissue Specific Origin, Development, and Pathological Perspectives of Pericytes

Langerhans Cells: Sensing the Environment in Health and Disease

Interleukin 2 therapy in severe atopic dermatitis

Enrichr: a comprehensive gene set enrichment analysis web server 2016 update

Adipocyte metabolism and obesity

Inhibition of triglyceride synthesis as a treatment strategy for obesity: lessons from DGAT1-deficient mice

Dendritic and Langerhans cells respond to Aβ peptides differently: implication for AD immunotherapy

Antigen sampling by intestinal M cells is the principal pathway initiating mucosal IgA production to commensal enteric bacteria

Selective IgA deficiency and the risk of asthma

Lung volume: a principle determinant of airway smooth muscle function

An immune-cell signature marks the brain in Alzheimer's disease

Inflammation inhibits GABA transmission in multiple sclerosis

The neuregulin, glial growth factor 2, diminishes autoimmune demyelination and enhances remyelination in a chronic relapsing model for multiple sclerosis

Inflammatory demyelination induces glia alterations and ganglion cell loss in the retina of an experimental autoimmune encephalomyelitis model

MerTK-mediated regulation of myelin phagocytosis by macrophages generated from patients with MS

TREM2 activation on microglia promotes myelin debris clearance and remyelination in a model of multiple sclerosis

Complement is activated in progressive multiple sclerosis cortical grey matter lesions

The complement system as a biomarker of disease activity and response to treatment in multiple sclerosis

Complement in multiple sclerosis: its role in disease and potential as a biomarker

Microglia and Inflammation in Alzheimer's Disease

Microglia in Alzheimer Disease: Well-Known Targets and New Opportunities

Apolipoprotein E and Alzheimer disease: pathobiology and targeting strategies

ApoE4: an emerging therapeutic target for Alzheimer's disease

TREM2 -a key player in microglial biology and Alzheimer disease

Apolipoprotein C-I is an APOE genotype-dependent suppressor of glial activation

The role of TREM2 in Alzheimer's disease

Apelin, a promising target for Alzheimer disease prevention and treatment

Apelin-13 Suppresses Neuroinflammation Against Cognitive Deficit in a Streptozotocin-Induced Rat Model of Alzheimer's Disease Through Activation of BDNF-TrkB Signaling Pathway

Loss of apolipoprotein E receptor LR11 in Alzheimer disease

Neuronal LR11/sorLA expression is reduced in mild cognitive impairment

A comprehensive study of the genetic impact of rare variants in SORL1 in European early-onset Alzheimer's disease

Role of the endothelium in inflammatory bowel diseases

Tumour Necrosis Factor Alpha in Intestinal Homeostasis and Gut Related Diseases

Pathway paradigms revealed from the genetics of inflammatory bowel disease

Genetics of inflammatory bowel disease from multifactorial to monogenic forms

Identification of mutations in a new gene encoding a FERM family protein with a pleckstrin homology domain in Kindler syndrome

Loss of Kindlin-1, a Human Homolog of the Caenorhabditis elegans Actin-Extracellular-Matrix Linker Protein UNC-112, Causes Kindler Syndrome

Extracellular matrix as a driver of progressive fibrosis

LOX-mediated collagen crosslinking is responsible for fibrosis-enhanced metastasis

Distinct Roles of FOXA2 and FOXA3 in Allergic Airway Disease and Asthma

Knockdown of lung phosphodiesterase 2A attenuates alveolar inflammation and protein leak in a two-hit mouse model of acute lung injury

Quantifying genetic effects on disease mediated by assayed gene expression levels

Orienting the causal relationship between imprecisely measured traits using GWAS summary data

Exploiting horizontal pleiotropy to search for causal pathways within a Mendelian randomization framework

RNA velocity of single cells

Perturb-seq: Dissecting molecular circuits with scalable single cell RNA profiling of pooled genetic screens

Massively parallel phenotyping of variant impact in cancer with Perturb-seq reveals a shift in the spectrum of cell states induced by somatic mutations

In vivo Perturb-Seq reveals neuronal and glial abnormalities associated with autism risk genes

Simultaneous epitope and transcriptome measurement in single cells

Chromatin Potential Identified by Shared Single-Cell Profiling of RNA and Chromatin

Fast, sensitive and accurate integration of single-cell data with Harmony

UMAP: Uniform Manifold Approximation and Projection for Dimension Reduction

A global reference for human genetic variation

Integrative analysis of 111 reference human epigenomes

Unique contribution of enhancer-driven and master-regulator genes to autoimmune disease revealed using functionally informed SNP-to-gene linking strategies

The positive false discovery rate: a Bayesian interpretation and the q-value

Annotations capturing cell type-specific TF binding explain a large fraction of disease heritability

The COVID-19 Host Genetics Initiative, a global initiative to elucidate the role of host genetic factors in susceptibility and severity of the SARS-CoV-2 virus pandemic

Lineage-Specific Genome Architecture Links Enhancers and Noncoding Disease Variants to Target Gene Promoters

A Compendium of Promoter-Centered Long-Range Chromatin Interactions in the Human Genome

Genetic effects on gene expression across human tissues

Functionally-informed fine-mapping and polygenic localization of complex trait heritability

Regulation of Cerebral Cortex Folding by Controlling Neuronal Migration via FLRT Adhesion Molecules

Sexually dimorphic diet-induced insulin resistance in obese tissue inhibitor of metalloproteinase-2 (TIMP-2)-deficient mice

Hyperphagia and leptin resistance in Tissue Inhibitor of Metalloproteinase-2 (TIMP-2) deficient mice

RNA Editing and Modifications in Mood Disorders

The inflammatory response in the pathogenesis of asthma

Interleukin-2-induced increased airway responsiveness and lung Th2 cytokine expression occur after antigen challenge through the leukotriene pathway

Interleukin-2-Dependent Allergen-Specific Tissue-Resident Memory Cells Drive Asthma

MUC5B and Idiopathic Pulmonary Fibrosis

Desmoplakin Variants Are Associated with Idiopathic Pulmonary Fibrosis

The COVID-19 Host Genetics Initiative, a global initiative to elucidate the role of host genetic factors in susceptibility and severity of the SARS-CoV-2 virus pandemic

Interferon-inducible antiviral effectors

Genetic mechanisms of critical illness in Covid-19

CCR5 Inhibition in Critical COVID-19 Patients Decreases Inflammatory Cytokines, Increases CD8 T-Cells, and Decreases SARS-CoV2 RNA in Plasma by Day 14

A single-cell and spatial atlas of autopsy tissues reveals pathology and cellular targets of SARS-CoV-2

MS-specific (D) or shared (H+D)) (columns), based on the Roadmap∪ABC-immune enhancer-gene linking strategy. e. UMAP embedding of scRNA-seq profiles (dots) from AD and healthy brain tissue, colored by cell type annotations (top) or disease status (bottom). f. Enrichments of AD disease progression programs for AD. Magnitude (E-score, dot size) and significance (-log10(P-value)

AD (red) brain samples. P-value: Fisher's exact test. h. Enrichments of AD cellular process programs for AD. Magnitude (E-score, dot size) and significance (-log10(P-value), dot color) of the heritability enrichment of inter-cell type cellular processes (AD-specific (D) or shared (H+D)) (columns), based on the Roadmap∪ABC-immune enhancer-gene linking strategy

In panels b,c,d,f, the size of each corresponding SNP annotation (% of SNPs) is reported in parentheses. Numerical results are reported in data file S1,2,3. Further details of all traits analyzed are provided in Supplementary Table 2. type annotations. b. Enrichments of healthy lung cell types for disease. Magnitude (E-score, dot size) and significance (-log10(P-value), dot color) of the heritability enrichment of healthy lung cell type programs (columns) for lung capacity or asthma (rows). c. UMAP embedding of scRNAseq profiles (dots) from asthma and healthy lung tissue

Magnitude (E-score, dot size) and significance (-log10(P-value), dot color) of the heritability enrichment of asthma disease progression programs (columns) for lung capacity or asthma (rows)

In panels b,d,e,g, the size of each corresponding SNP annotation (% of SNPs) is reported in parentheses. Numerical results are reported in data file S1,2,3. Further details of all traits analyzed are provided in Supplementary Table 2. significance (-log10(P-value), dot color) of the heritability enrichment of immune cell type programs constructed for each dataset size. k. Specificity index (y axis; see Methods) for immune cell type programs generated from subsampled PBMC scRNA-seq data at varying numbers of cells. l,m. Magnitude (E-score, dot size) and significance (-log10(P-value), dot color) of the heritability enrichment of immune cell type programs (columns) for 5 blood cell traits (l) and 11 autoimmune traits (m). n. Mean gene set expression score (dot color) from the baseline cell scoring approach

Supplementary Table 2 . Diseases and complex traits analyzed. We analyzed 60 diseases and complex traits with genetic correlation <= 0.9 and report the publication and sample size of each study. 

Supplementary Fig. 15 . Analysis of disease progression programs using alternative Roadmap∪ABC enhancer-gene linking strategies. Magnitude (E-score, dot size) and significance (-log10(P-value), dot color) of the heritability enrichment of disease progression programs (columns) in UC (colon cells) using Roadmap∪ABC-immune (a), asthma (lung cells) using Roadmap∪ABC-immune (b), and MS (brain cells) using Roadmap∪ABC-brain (c). Details for all traits analyzed are in Supplementary Table 2.

Supplementary Fig. 16 . Analysis of disease progression programs across all tissues and traits. Magnitude (E-score, dot size) and significance (-log10(P-value), dot color) of the heritability enrichment of disease progression programs (columns) from UC, MS, Alzheimer's, asthma and pulmonary fibrosis (labels on top, color code, legend), for GWAS summary statistics of diverse traits and diseases (rows), based on the Roadmap∪ABC enhancer-gene linking strategy for the corresponding tissue. Details for all traits analyzed are in Supplementary Table 2 . See Data Availability for higher resolution version of this figure.